NCT02315768View on ClinicalTrials.gov

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

August 26, 2015

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

GA101

DRUG

Ibrutinib

Trial Locations (1)

92093

UCSD Moores Cancer Center, La Jolla

Sponsors

Collaborators (1)

Pharmacyclics LLC.

All Listed Sponsors

collaborator

Pharmacyclics LLC.

INDUSTRY

lead

University of California, San Diego

OTHER